Compounded semaglutide and tirzepatide in 2026: what a brand can still offer

Is compounded semaglutide legal in 2026? For a brand operator the honest answer has three parts. Large-batch compounding by 503B outsourcing facilities is effectively closed, and FDA is moving to close it formally. Patient-specific compounding by a 503A pharmacy survives, but only for a patient whose prescriber documents a clinical reason the approved product will not serve, and that reason cannot be a marketing default. A brand built this year therefore runs on branded access, with compounding as an exception path. This post lays out the timeline, the two compounding categories, the enforcement picture, and what all of it means for a medication list.

The timeline, from shortage delisting to the Fifth Circuit

Compounding of semaglutide and tirzepatide was never a standing permission. It rested on one fact: both drugs sat on FDA's drug shortage list, and federal law lets 503A pharmacies and 503B outsourcing facilities compound a drug that is in shortage. When the shortage ends, the permission ends with it. The dates matter because pharmacy boards and plaintiffs' lawyers use them as bright lines.

According to FDA's own statement on its GLP-1 compounding policy, the agency declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025. It then set wind-down periods so pharmacies could work through inventory and move patients across. For tirzepatide, FDA's enforcement discretion for 503A pharmacies ended February 18, 2025, and for 503B facilities on March 19, 2025. For semaglutide, the 503B window ran through May 22, 2025. The same FDA page, updated April 1, 2026, states that neither drug is on the drug shortage list or on the 503B bulks list.

Two further steps came in 2026. On April 30, FDA proposed a rule that would exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list outright, as reported by Drug Topics and in law-firm alerts. The comment period closed June 29, 2026, and as of this writing no final rule has been published. Then, in a decision summarized in law-firm alerts in late August 2026, the Fifth Circuit affirmed FDA's shortage delistings in Outsourcing Facilities Association v. FDA, No. 25-10758. The trade group's argument that FDA had acted too early did not carry. At the federal level the question is settled. What remains is the narrow patient-specific pathway and the enforcement mop-up.

What a 503A pharmacy can still do

A 503A pharmacy is a state-licensed pharmacy that compounds a drug for an identified patient on a valid prescription. Its first regulator is its state board of pharmacy, and the federal rules that apply to it are narrower than the rules for outsourcing facilities. The 503A compounding entry covers the basics. What matters here is the single provision that governs GLP-1s now that the shortage is over.

Section 503A bars a pharmacy from compounding, regularly or in inordinate amounts, any drug that is essentially a copy of a commercially available drug product. A compounded semaglutide injection is a copy of Wegovy or Ozempic on its face. The statute's exception is a prescriber's determination, documented on the prescription, that a change made for an identified patient produces a significant difference for that patient. FDA's guidance on essentially-a-copy compounding under 503A gives examples such as removing an ingredient the patient cannot tolerate, and it says plainly that a lower price is not a significant difference.

That is why a marketing default cannot survive. A patient-specific determination made before the patient exists is not patient-specific. If a brand's intake flow, protocol document or provider script produces the same documented reason for every patient, a pharmacy board or a plaintiff will read it as a copy program dressed as an exception. The determination has to originate with the prescriber's assessment of that patient, and the pharmacy has to be able to show it prescription by prescription.

A patient-specific determination made before the patient exists is not patient-specific.

The practical result is that compounded semaglutide and tirzepatide remain lawful in 2026 in one narrow lane. A licensed prescriber, seeing a specific patient, documents a clinical reason the approved product will not serve, and a 503A pharmacy licensed in the patient's state fills that prescription. The volume that lane produces is a small fraction of what a weight-loss brand needs, and it should be treated as an exception path, never as a revenue line.

What a 503B facility cannot do

A 503B outsourcing facility registers with FDA, follows current good manufacturing practice, and may compound in bulk without a patient-specific prescription, selling to clinics and prescribers for office stock. The 503B outsourcing facility entry goes deeper. The point for GLP-1s is that a 503B facility may only use a bulk drug substance that appears on FDA's 503B bulks list or that is on the shortage list at the time of compounding.

Neither condition holds for semaglutide or tirzepatide, per FDA's April 1, 2026 page update. There is no essentially-a-copy exception for a 503B facility to reach for; the bulks list is the gate. The April 2026 proposed rule, if finalized as the trade press describes it, would remove even the theoretical route by excluding all three GLP-1s from the list. In operating terms, the large-batch supply that made low-cost, high-volume compounded programs possible in 2023 and 2024 is gone.

Operators still receive offers for 503B-sourced semaglutide vials. The honest ways that could be true have run out. Inventory compounded before the wind-down dates has long since passed any reasonable beyond-use date. A partner offering bulk vials in 2026 is mislabeling a 503A operation, sourcing from an unregistered facility, or bringing in active ingredient outside the approved channels. None of those is a position a brand wants to be underwriting with its name on the storefront.

What state pharmacy boards are enforcing

Federal law sets the outer boundary. Day-to-day enforcement against a compounding pharmacy comes from its state board, and from the boards of every state it ships into under a nonresident licence. Boards hold the tools that matter: inspection, records demands and licence discipline. They do not need FDA to act first.

The patterns visible in board actions and inspection guidance follow the statute. Inspectors compare the volume of a compounded GLP-1 against the number of distinct patients and prescribers, and look for the documented reason on each prescription. They ask where the active pharmaceutical ingredient came from, whether the supplier is FDA-registered, and whether a certificate of analysis exists for each lot. They look at labeling, at beyond-use dating, and at whether a sterile product was made under a sterile permit. A nonresident pharmacy shipping into a state without that state's licence, or without the sterile endorsement that state requires, is an easy case for a board to make.

For a brand, the exposure is indirect but real. The prescriptions came from the brand's affiliated practice, the patients are the brand's, and the marketing that drove the volume carries the brand's name. When a board asks a pharmacy for records, the brand's protocols and intake data are what those records describe. Medical boards read the same file from the prescriber's side.

Marketing letters from FDA and what the FTC watches

Two federal agencies police how a compounded GLP-1 is talked about. FDA's Office of Prescription Drug Promotion has sent letters to telehealth and compounding operators over GLP-1 promotion, as reported by STAT and other outlets. The recurring problems are familiar: presenting a compounded product as if it were FDA-approved, borrowing a manufacturer's brand name to describe a compounded version, leaving out risk information, and implying equivalence to the approved product. Manufacturers have become enforcers in their own right. STAT reported on July 21, 2026 that Novo Nordisk sued Eli Lilly over GLP-1 advertising, and the press has covered manufacturer suits against telehealth companies over compounded-drug marketing through 2026.

The FTC works from a different statute. Its concern is substantiation of weight-loss claims, endorsement and testimonial rules, and the terms of the subscription the patient signs. On subscriptions specifically, the FTC's 2024 click-to-cancel amendments to the Negative Option Rule were vacated by the Eighth Circuit, and the agency issued an advance notice of proposed rulemaking on March 11, 2026 to start again. The underlying rule and the FTC's general authority against unfair and deceptive practices did not go anywhere. A brand's ad copy and checkout flow should be built as if the vacated provisions were in force, because several state laws reach the same conduct. The weight-loss marketing claims guide covers the specifics.

What this means for a brand's medication list in 2026

Put the pieces together and the medication list for a GLP-1 brand launched in 2026 looks different from one launched two years earlier. Branded products come first: the injectable products from both manufacturers through their cash-pay channels, and oral semaglutide, which is covered separately on this site. Compounded semaglutide or tirzepatide sits on the list as an exception, available when a prescriber documents a patient-specific reason, filled by a 503A pharmacy licensed in the patient's state, and never named in an ad.

Building the list this way changes the economics, and operators should be clear-eyed about it. The margin that compounded programs carried is not coming back. The brand's revenue is the consult and the program fee, and the medication passes through at whatever the manufacturer charges. That is also the structure that survives scrutiny, because nobody in the chain earns more by steering a patient toward the compounded option.

Tessic Health's weight-loss clinics are built on this list. The pharmacy network dispenses at 0% medication markup, so a branded fill and a compounded exception cost the brand the same thing, which is nothing beyond the medication itself. Providers licensed in all 50 states make the patient-specific determination where one exists, and the documentation lives in the record where a board can find it. The GLP-1 clinic launch guide lays out the rest of the setup.

Signs a pharmacy partner is on the wrong side

Before signing a pharmacy or platform agreement, look for these signals. Any one of them is reason to slow down and ask for documents.

• Bulk vials of semaglutide or tirzepatide offered from a 503B source in 2026, with no explanation of how that squares with FDA's bulks list.
• A standard documented reason supplied by the pharmacy or platform for every prescription, or a protocol that tells providers what reason to write.
• Compounded product priced per vial to the brand rather than dispensed to a named patient on a prescription.
• A nonresident licence list the pharmacy cannot produce on request, or one that does not distinguish sterile from non-sterile permits.
• Active ingredient sourced from a supplier the pharmacy will not name, or with no certificate of analysis per lot.
• Marketing templates that use the manufacturer's brand names to describe a compounded product.
• A markup on the compounded product that gives the platform a reason to prefer it over the branded fill.

Questions operators ask

Can a brand still advertise compounded semaglutide? The safe answer is no. Compounded products are not FDA-approved and cannot be promoted as such, and an ad for a compounded GLP-1 is an admission that the product is a default rather than a patient-specific exception. Advertise the program and the clinical service, and let the prescriber decide the product.

Does a different dose or an added vitamin make a compounded product lawful? FDA's essentially-a-copy guidance is skeptical of changes made to get around the copy limit rather than to serve an identified patient. A change has to produce a significant difference for that patient, documented by the prescriber, and the same change applied to everyone is not patient-specific.

What happens to patients already on a compounded product? That is a clinical transition question for the affiliated practice, and the answer runs through the prescriber. From the operator's side, the job is to make sure the branded fill is available on the storefront and the pharmacy can dispense it in the patient's state, so the transition does not stall on logistics.

Does the Fifth Circuit ruling change anything for 503A pharmacies? It confirms the delistings, which is what closed the shortage-era pathway. The essentially-a-copy exception was never about the shortage, and it remains available exactly as narrow as it always was.

Has the April 2026 proposed rule been finalized? As of this writing, no. The comment period closed June 29, 2026 and a final rule has not been published. It would change little in practice, because the drugs are already off the 503B bulks list; its effect is to keep them from returning.

The business model that survives 2026 sells a clinical service at an honest price and passes the medication through at the manufacturer's price. Compounding, where it exists at all, is the documented exception it was always meant to be.